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Objective: This study evaluates the feasibility of off-pump native aortic valve removal in preparation for trans-
apical aortic valve replacement. Off-pump aortic valve replacement is performed by balloon predilatation of the
native valve followed by insertion of a stented prosthesis. In patients with calcified annuli and cusps, particulate
embolization, suboptimal prosthesis sizing, and perivalvular leaks may occur. Therefore, native valve removal
may improve outcomes after transapical aortic valve replacement.
Methods: The aortic cusps were sequentially removed from 10 pigs in an off-pump procedure. A temporary valve
was inserted percutaneously into the ascending aorta to prevent aortic regurgitation. The electrocardiogram, cor-
onary blood flow, and arterial, left atrial, and ventricular pressures were continuously monitored.
Results: Removal of the aortic cusps caused a drop in diastolic arterial pressure and its equalization with left ven-
tricular diastolic pressure. Systolic pressure decreased by 13.5%. Left atrial pressure increased by 86.0%. Cor-
onary blood flow decreased by 39.9% and its pattern changed from mostly diastolic to mostly systolic.
Electrocardiographic signs of ischemia appeared almost immediately. Percutaneous insertion of a temporary
valve in the ascending aorta increased diastolic pressure and caused a tendency toward echocardiographic nor-
malization.
Conclusions: Aortic valve removal in a healthy beating heart causes acute massive aortic regurgitation, hemo-
dynamic instability, and the rapid onset of myocardial ischemia. Reduction of left ventricular volume overload,
by placement of a temporary valve in the ascending aorta, mitigates myocardial distress, helps stabilize hemody-
namic parameters, and may be a useful tool to allow surgical manipulations of the aortic valve and annulus during
transapical aortic valve replacement procedures.Aortic valve stenosis is one of the most common types of
acquired valve disease,1 and it is conventionally treated
with aortic valve replacement (AVR) during open cardiac
operations with cardiopulmonary bypass and cardioplegic
arrest of the heart. Minimally invasive approaches aim to im-
prove the life expectancy and quality of life in patients who
cannot currently benefit from conventional surgical proce-
dures. New technologies have led progressively toward
less invasive cardiac procedures, and minimally invasive re-
placement, reconstruction, and implantation of heart valves
are currently important focuses of cardiac research.2,3
The first attempts to treat aortic stenosis in a nonsurgical
way began with balloon aortic valvuloplasty in 1985. This
procedure was gradually abandoned because of suboptimal
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sutured onto balloon-expandable stents for catheter-based
deployment.7 These stented valves opened new frontiers in
aortic valve implantation. In 2002, Cribier and associates8
used this technique for the treatment of calcified aortic steno-
sis in a patient whose condition was considered inoperable
by conventional methods. In the following years, ante-
grade/transapical, retrograde/percutaneous, and valve-in-
valve variations of this technique were reported.9,10
Continued development and improvements in valve re-
placement by both percutaneous and transapical approaches
have expanded the clinical indications for minimally inva-
sive AVR, especially in the treatment of elderly and high-
risk patients.11-14 However, neither technique removes the
native cusps or decalcifies the annulus, important steps dur-
ing open AVR.15 Instead, simple balloon predilatation is
used to prepare the annulus for the implantation of the pros-
thesis.10 Patient–prosthesis mismatch, embolization of cal-
cium debris, coronary flow (CF) obstruction, and onset of
perivalvular leaks have been reported after aortic valve
implantation with these techniques.16-18
Resection of the native calcified aortic valves before
transapical or percutaneous AVR may improve out-
comes.19,20 However, removing the aortic valve in an off-
pump procedure leads to acute, severe aortic regurgitation.
This study was undertaken to determine the technicalrgery c August 2009
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AP ¼ arterial pressure
AVR ¼ aortic valve replacement
CF ¼ coronary flow
ECG ¼ electrocardiogram
LAP ¼ left atrial pressure
LV ¼ left ventricle (ventricular)
feasibility of beating heart, off-pump, aortic valve removal
in preparation for transapical or percutaneous AVR. We
evaluated the hemodynamic effects and physiologic re-
sponse of the heart to transapical removal of aortic cusps
in an off-pump procedure in swine and the protective effects
of placing a temporary valve in the ascending aorta to min-
imize hemodynamic instability during the procedure.
METHODS
Surgical Procedure
After we had obtained institutional approval, 8 domestic cross pigs
(average weight 96.4 kg, range 83–105 kg) were anesthetized, intubated,
and mechanically ventilated.
Arterial pressure (AP), left atrial pressure (LAP), and left ventricular
(LV) pressure were continuously monitored and recorded.
The left anterior descending artery was isolated and a 2-mm flow probe
was positioned around it to continuously monitor CF.
A cutting device was inserted into the LV through the apex and the three
aortic cusps were sequentially removed by rotating the tool 120 to cut each
cusp (Figure 1). At most, two attempts were needed to grab and cut each
cusp, and the removal of all three cusps took less than 4 minutes in all cases.
The procedure was performed under real-time epicardial echocardiographic
guidancewith a transesophageal probe resting on the lateral surface of the heart
at the level of the right atrium (Figure 2, A and B). Finally, a temporary valve
was inserted, in a retrograde fashion, through the right carotid artery and
advanced into the ascending aorta, first to a supracoronary position and then
at the level of the aortic annulus, in the orthotopic position. As before, pres-
sures, CF, and the electrocardiogram (ECG) were monitored and recorded.
At the end of the procedure, the animals were humanely killed and the hearts
were harvested for necroscopic inspection.All data were collectedwithDataQ
software and hardware DI 510 (DataQ Instruments, Akron, Ohio).The Journal of Thoracic and CCutting Device and Temporary Valve
The cutting device was manufactured from two pieces of hypodermic
seamless tubing (Figure 3). One extremity of the smaller diameter tube
was sharpened to a knife edge for cutting and slid freely inside the larger
diameter tube, which had a sharpened notched section close to the distal
end. When the cusp was captured in the notch of the larger tube, the smaller
tube was moved forward to cut the cusp, which remained trapped inside the
device and was removed (Figure 1).
The temporary valve was mounted on a wire and consisted of a conical
membrane with chordae, thereby resembling a parachute. It was previously
described by Vandenberghe and colleagues.21 Figure 4 shows the final
assembly.
Statistical Analysis
Continuous variables are presented as mean over 10 consecutive
beats  standard deviation. Data were processed with Statistical
Package for Social Sciences 13.0 software (SPSS Inc, Chicago, Ill).
One-way analysis of variance was performed to compare parameters
under different conditions, followed by a multiple pairwise comparison
procedure (Tukey test). Assumptions of normality were checked and
met. The Holm–Sidak method was used to increase the power of the
analysis. The Pearson product–moment r coefficient was calculated to
evaluate correlations.
RESULTS
Hemodynamic Effects of Removing the Aortic Cusps
Removal of the three aortic cusps caused a dramatic and
immediate drop in diastolic AP (P< .001) and its equaliza-
tion with LV end-diastolic pressure22 (Figure 5 and Table 1).
Systolic AP decreased by 13.5% (P< .001) and LAP in-
creased by 86.0% (P< .05). Average CF decreased by
49.9% (P< .05), and its pattern changed from mostly dia-
stolic to mostly systolic (Figure 5). ECG changes (T-wave
inversion) appeared an average of 30.8 seconds (range:
17–42 seconds) after introduction of the cutting device
into the LV apex. Massive regurgitation was seen by echo-
cardiographic imaging (Figure 2, B). Thus, as expected, re-
moval of the aortic cusps from the beating heart significantly
altered CF and pressures. However, these changes were not
immediately lethal and were tolerated for up to 30 minutes,
despite the early onset of ECG ischemic changes.E
T
/BFIGURE 1. The procedure for transapical removal of the aortic cusps. A, Insertion of the cutting device into the left ventricle through the apex. B, Capturing
and cutting the cusp. C, Removing the cutting device and captured cusp from the left ventricle. This procedure was done for each cusp by simply rotating the
cutting device 120 counterclockwise.ardiovascular Surgery c Volume 138, Number 2 469
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To test whether a temporary device could reduce regurgi-
tation and acute LV volume overload during debridement
before transapical AVR, we inserted a temporary valve
with a parachute-like design into the ascending aorta after
removal of the aortic cusps (Figure 6). We previously tested
this valve in a mechanical cardiovascular simulator and
found that the valve increased output and decreased regurgi-
tation.21
After placement of the temporary valve in the supracoro-
nary position, diastolic AP increased (P< .001) and a ten-
dency toward T-wave normalization was noted (Figure 5).
Unexpectedly, absolute CF decreased further compared
with the no-cusp situation, although the difference was not
statistically different (Table 1).
When the temporary valve was pushed down into the or-
thotopic position, CF significantly improved (P< .05), al-
though the other hemodynamic parameters (LAP, diastolic
AP, and systolic AP) did not change in a significant manner.
In conclusion, placing the temporary valve in the supra-
coronary position only caused a tendency toward normaliza-
FIGURE 2. Echocardiographic monitoring of cusp removal and aortic re-
gurgitation. A, Epicardial long-axis echocardiogram showing the cutting
device (CD) inserted through the left ventricle (LV) grabbing the noncoro-
nary cusp (NCC). The left main coronary artery (LCA) and left atrium (LA)
are also visible. B, Massive aortic regurgitation (AR) immediately after the
removal of the aortic valve. VP, Valve plane.470 The Journal of Thoracic and Cardiovascular Sution of the diastolicAP,whereas pushing the temporary valve
into the orthotopic position also significantly improved the
CF. Systolic AP and LAP were not affected in either case.
After all procedures were completed, the hearts were har-
vested for necroscopic inspection. In all cases, cusp removal
and insertion of the temporary valve caused neither anatomic
abnormalities nor damage to the mitral subvalvular appara-
tus, aortic root and annulus, or aortic wall (Figure 7).
DISCUSSION
Between 30% and 60% of patients affected by severe
aortic stenosis are not treated surgically, usually owing to
advanced age and comorbidities.24 A feasibility study, ap-
proved by the Food and Drug Administration, of a less inva-
sive transcatheter/transapical approach to AVR in high-risk,
elderly patients was initiated in several centers. The proce-
dure was found to be feasible but carried considerable risk.
Early experience showed an in-hospital/30-day mortality
of 22.5%, with a total mortality of 37.5% at 1 year,25
although other more recent publications have shown lower
mortality and a low risk of embolization.26 In this study,
we investigated the feasibility of performing a complete
FIGURE 3. The cutting device. Inner tube (1). Outer tube (2).
FIGURE 4. The assembled temporary valve. PU, Polyurethane; ePTFE,
expanded polytetrafluoroethylene.rgery c August 2009
Salizzoni et al Evolving Technology/Basic ScienceFIGURE 5. Electrical activity and hemodynamics after aortic cusp removal and temporary valve placement. Two-second recordings of electrical activity,
arterial, atrial, and ventricular pressures, and coronary flow during the four experimental conditions tested. A representative experiment (pig 8) is shown. AP,
Arterial pressure (plotted in black); LVP, left ventricular pressure (plotted in gray). LAP, left atrial pressure; CF, coronary flow. In the plots for CF, the hor-
izontal gray lines represent zero. EKG, Electrocardiogram.E
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uation. The rationale underlying this approach is that cusp
removal and annular ‘‘cleanup’’ before transapical or trans-
femoral AVR might yield improved procedural results.
In this study, the sudden onset of severe aortic regurgita-
tion after off-pump removal of the aortic cusps in a normal
beating heart caused profound changes in AP, CF, and
LAP. This is consistent with the results of others, although,
in these prior studies, the aortic valve was damaged but not
completely removed.27-29 In our experiments, all three aortic
cusps were completely removed. The LV tolerated these
acute changes for some time, but myocardial ischemia
appeared soon thereafter. Placement of a temporary valve
in the ascending aorta reduced LV volume overload and
mitigated myocardial distress.
An immediate consequence of aortic cusp removal was
a significant decrease in CF (39.9% from baseline), with
subsequent appearance of ECG indications of ischemia.
After placement of a temporary valve in the supracoronary
position, CF decreased by an additional 24.8%, most likely
as a consequence of the almost total loss of the diastolic
component to blood flow. Pushing the catheter-based tempo-
rary valve deeper into the LV outflow tract (orthotopic,The Journal of Thoracic andsubcoronary position) caused the CF to return to a near
physiologic level, with a difference of only14.0% com-
pared with the baseline situation. This small difference
may be due simply to a suboptimal valve design or to the
fact that it is quite difficult to place and retain the temporary
valve in the exact location of the native valve.
LAP increased dramatically after the removal of the
cusps, and the temporary valve was unable to alleviate this
in either the orthotopic or supracoronary position. Perhaps
LAP did not recover because the experiment was not contin-
ued for enough time to allow complete myocardial recovery.
TABLE 1. In vivo hemodynamic measurements
Hemodynamic
measurements Baseline No cusps Supracoronary Orthotopic
Diastolic AP
(mm Hg)
53.4  3.7 14.7  2.5* 33.8  2.2*y 34.0  1.9*y
Systolic AP
(mm Hg)
86.5  3.0 74.8  5.0* 80.6  6.8 84.5  5.4y
LAP (mm Hg) 8.8  1.0 16.5  2.8 15.2  2.4* 14.5  0.9*
CF (mL/min) 41.3  7.3 24.8  3.5* 18.6  1.6* 35.5  11.0z
AP, Arterial pressure; LAP, left atrial pressure; CF, coronary flow. *Differs from base-
line; P< .05. yDiffers from no cusps; P< .05. zDiffers from supracoronary; P< .05.Cardiovascular Surgery c Volume 138, Number 2 471
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pigs could maintain adequate hemodynamics as long as 30
minutes after induction of massive aortic regurgitation. Im-
plantation of a temporary valve in the ascending aorta limits
LV volume overload and has the potential to prolong this
period of hemodynamic stability. Eventually, though, myo-
cardial ischemia ensues owing to reduction in CF, and he-
modynamic deterioration follows. In theory, the addition
of a percutaneous (transfemoral) system allowing direct can-
nulation of the coronary ostia and coronary perfusion at
FIGURE 6. Behavior of the temporary valve in ascending aorta, A and B,
Schematic design. C and D, Echocardiographic images. A and C, Tempo-
rary valve closed during systole to permit blood flow into the ascending
aorta. B and D, Open in diastole to prevent aortic regurgitation. PU, Poly-
urethane leaflets; W, guidewire.472 The Journal of Thoracic and Cardiovascular Sura physiologic pressure and flow should allow longer periods
of hemodynamic stability. Further investigation is needed to
determine whether this additional step is feasible and has the
potential to increase safety in a hybrid approach to transap-
ical AVR.
In these experiments, we accessed the heart via a sternot-
omy and then inserted the cutting device into the LV apex.
We chose the direct LV apical approach instead of the
peripheral retrograde approach because transfemoral access
limits the size of the surgical devices and decreases the pre-
cision of the surgical manipulations.30 Although these ex-
periments were performed via sternotomy, the procedure
could be easily done in a minimally invasive manner through
a left minithoracotomy or a subxiphoidal incision. A periph-
eral, retrograde approach may also be possible with differ-
ently designed instruments.
Limitations
The most difficult limitation to resolve is the absence of
calcific aortic stenosis in our animal model. However, we
are not aware of any animal model for this condition. With
a healthy aortic valve, it is easy to cut the cusps, but it will
undoubtedly be more difficult to remove the cusps and de-
bride the aortic annulus when calcifications are present. Ad-
ditionally, in this pilot study, we did not attempt to prevent
embolic events caused by the procedure. Future experiments
are planned with a new temporary valve that incorporates
a net in the distal portion to capture solid emboli. Finally,
we learned that a normal heart is able to tolerate acute severe
aortic regurgitation for short time periods; however, we do
not know whether a hypertrophic heart, as in a patient
with aortic valve stenosis, would behave similarly.
In summary, this study was undertaken to determine the
technical feasibility of removing the aortic cusps in an off-
pump, beating-heart model and to evaluate the effects of
the insertion of a temporary valve in the ascending aorta to
minimize hemodynamic instability during the procedure.
Although further testing is needed and modifications in the
instrumentation may be necessary, this study clearlyFIGURE 7. The aortic root and cusps after the procedure. A, The aortic root at the end of the experiment. RCA, Right coronary artery ostium; LCA, left
coronary artery ostium; NCC, cut noncoronary cusp; IVS, interventricular septum, which in pigs is thicker than in humans.23 B, Removed aortic cusps.gery c August 2009
T
/B
S
Salizzoni et al Evolving Technology/Basic Sciencedemonstrates the feasibility of endovascular resection of the
aortic cusps as a possible component of future transapical,
off-pump AVR operations.
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